Jelena Perisic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jelena Perisic has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Bojan Maričić
Cardiology Clinic, University Clinical Center Niš, 18000Niš, Serbia
2 shared publications - Sonja Dakic
Cardiology Clinic, University Clinical Center Niš, 18000Niš, Serbia
2 shared publications - Svetlana Apostolovic
Cardiology Clinic, University Clinical Center Niš, 18000Niš, Serbia
2 shared publications - Tamara Filipović
Cardiology Clinic, University Clinical Center Niš, 18000Niš, Serbia
2 shared publications - Andjela Dankovic
Faculty of Medicine, University of Nis, Bulevar dr Zorana Djindjica 81, 18000 Nis, Serbia
1 shared publication - Bane Spasovic
Cardiology Clinic, University Clinical Center Niš, 18000Niš, Serbia
1 shared publication
Latest Publications
- Open Access
- 11 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8830
Invasive Management and 1-Year Outcomes in Patients Aged ≥75 Years with Acute Coronary Syndrome: Age and Clinical Vulnerability
Background/Objectives: Older adults with acute coronary syndrome (ACS) are clinically heterogeneous, and treatment decisions should not rely on chronological age alone. We examined associations of age and clinical vulnerability with coronary angiography, subsequent percutaneous coronary intervention (PCI), and mortality in patients aged ≥75 years. Methods: We retrospectively studied 1043 consecutive patients hospitalized with ACS between January 2021 and April 2026. Clinical vulnerability was assessed using the exploratory, study-specific Senior ACS Clinical Vulnerability Score (SAF-75). Results: Mean age was 81.0 years; 47.6% were women. Coronary angiography was performed in 571 patients (54.7%) and PCI in 208 (19.9%). Angiography declined from 68.6% at age 75–79 years to 30.1% at ≥85 years. Age was independently associated with lower odds of angiography (OR 0.86 per year, 95% CI 0.82–0.89; p < 0.001), but not with subsequent PCI among patients undergoing angiography (OR 1.01, 95% CI 0.95–1.06; p = 0.852). In-hospital and Kaplan–Meier estimated 1-year mortality were 18.1% and 35.7%. Greater vulnerability was associated with lower angiography use and higher mortality; no independent association with PCI after angiography was detected. Conclusions: Age-related and vulnerability-related differences were most evident at angiography selection. SAF-75 was strongly associated with prognosis but requires external validation.
- 11 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8830
Open AccessInvasive Management and 1-Year Outcomes in Patients Aged ≥75 Years with Acute Coronary Syndrome: Age and Clinical Vulnerability
Background/Objectives: Older adults with acute coronary syndrome (ACS) are clinically heterogeneous, and treatment decisions should not rely on chronological age alone. We examined associations of age and clinical vulnerability with coronary angiography, subsequent percutaneous coronary intervention (PCI), and mortality in patients aged ≥75 years. Methods: We retrospectively studied 1043 consecutive patients hospitalized with ACS between January 2021 and April 2026. Clinical vulnerability was assessed using the exploratory, study-specific Senior ACS Clinical Vulnerability Score (SAF-75). Results: Mean age was 81.0 years; 47.6% were women. Coronary angiography was performed in 571 patients (54.7%) and PCI in 208 (19.9%). Angiography declined from 68.6% at age 75–79 years to 30.1% at ≥85 years. Age was independently associated with lower odds of angiography (OR 0.86 per year, 95% CI 0.82–0.89; p < 0.001), but not with subsequent PCI among patients undergoing angiography (OR 1.01, 95% CI 0.95–1.06; p = 0.852). In-hospital and Kaplan–Meier estimated 1-year mortality were 18.1% and 35.7%. Greater vulnerability was associated with lower angiography use and higher mortality; no independent association with PCI after angiography was detected. Conclusions: Age-related and vulnerability-related differences were most evident at angiography selection. SAF-75 was strongly associated with prognosis but requires external validation.
- Open Access
CYP3A4, CYP3A5, and CYP4F2 Polymorphisms and Bleeding Risk in Ticagrelor-Based Dual Antiplatelet Therapy
Background and Objectives: Ticagrelor reduces ischemic events in acute coronary syndrome (ACS) but increases bleeding risk. Clinical predictors of bleeding are well established; the contribution of cytochrome P450 polymorphisms involved in ticagrelor metabolism remains uncertain, with conflicting reports in the literature. We examined the association of CYP3A4* 22 (rs 35599367), CYP3A5* 3 (rs 776746), and CYP4F2 (rs3093135) with bleeding in a Serbian ACS cohort. Materials and Methods: This prospective, single- center observational study enrolled 105 consecutive ACS patients undergoing percutaneous coronary intervention (PCI) or medical management after coronary angiography and receiving dual antiplatelet therapy (DAPT) with acetylsalicylic acid and ticagrelor at the University Clinical Center Niš between January 2024 and the end of May 2025. Bleeding events occurring during the index hospitalization and the six-month follow-up were classified according to the Bleeding Academic Research Consortium (BARC) criteria. Genotyping used TaqMan assays. Associations with bleeding were assessed using Firth’s penalized logistic regression, with multivariable adjustment for age and renal function. Severity-stratified analyses and gradient-boosted machine learning (XGBoost with SHAP) were performed as exploratory analyses. Results: Thirteen patients (12.4%) experienced bleeding (nine minor [BARC 1/2], four major [BARC 3/5]). Age ≥ 75 years (univariable OR 7.62, p = 0.001) and eGFR < 60 mL/min/1. 73 m 2 (OR 3.68, p = 0.006) were the strongest predictors. CYP3A5 *1 carrier status was univariably associated with bleeding (OR 4.16, p = 0.043) but did not remain significant after adjustment for age and renal function, and *1 carriers were significantly older and more likely to have impaired renal function. No genotype was associated with major (BARC 3/5) bleeding. The apparent effect was concentrated in minor bleeding (BARC 1/2 rate: 30.8% versus 5.5%), with no major events among *1 carriers. CYP 3 A 4* 22 (OR 1.37, p = 0.109) and CYP 4 F 2 (OR 1.17, p = 0.111) showed no association. Machine-learning analyses confirmed eGFR and age as the dominant predictors. Conclusions: In this Serbian ACS cohort, clinical factors—particularly advanced age and impaired renal function—dominated the prediction of bleeding risk. The CYP3A5 signal was largely explained by baseline imbalances in age and renal function. CYP 3 A 4* 22 and CYP 4 F 2 polymorphisms did not contribute additional predictive information. Preemptive genotyping for these variants is unlikely to materially improve bleeding-risk assessment beyond standard clinical evaluation in patients of this type.
Open AccessCYP3A4, CYP3A5, and CYP4F2 Polymorphisms and Bleeding Risk in Ticagrelor-Based Dual Antiplatelet Therapy
Background and Objectives: Ticagrelor reduces ischemic events in acute coronary syndrome (ACS) but increases bleeding risk. Clinical predictors of bleeding are well established; the contribution of cytochrome P450 polymorphisms involved in ticagrelor metabolism remains uncertain, with conflicting reports in the literature. We examined the association of CYP3A4* 22 (rs 35599367), CYP3A5* 3 (rs 776746), and CYP4F2 (rs3093135) with bleeding in a Serbian ACS cohort. Materials and Methods: This prospective, single- center observational study enrolled 105 consecutive ACS patients undergoing percutaneous coronary intervention (PCI) or medical management after coronary angiography and receiving dual antiplatelet therapy (DAPT) with acetylsalicylic acid and ticagrelor at the University Clinical Center Niš between January 2024 and the end of May 2025. Bleeding events occurring during the index hospitalization and the six-month follow-up were classified according to the Bleeding Academic Research Consortium (BARC) criteria. Genotyping used TaqMan assays. Associations with bleeding were assessed using Firth’s penalized logistic regression, with multivariable adjustment for age and renal function. Severity-stratified analyses and gradient-boosted machine learning (XGBoost with SHAP) were performed as exploratory analyses. Results: Thirteen patients (12.4%) experienced bleeding (nine minor [BARC 1/2], four major [BARC 3/5]). Age ≥ 75 years (univariable OR 7.62, p = 0.001) and eGFR < 60 mL/min/1. 73 m 2 (OR 3.68, p = 0.006) were the strongest predictors. CYP3A5 *1 carrier status was univariably associated with bleeding (OR 4.16, p = 0.043) but did not remain significant after adjustment for age and renal function, and *1 carriers were significantly older and more likely to have impaired renal function. No genotype was associated with major (BARC 3/5) bleeding. The apparent effect was concentrated in minor bleeding (BARC 1/2 rate: 30.8% versus 5.5%), with no major events among *1 carriers. CYP 3 A 4* 22 (OR 1.37, p = 0.109) and CYP 4 F 2 (OR 1.17, p = 0.111) showed no association. Machine-learning analyses confirmed eGFR and age as the dominant predictors. Conclusions: In this Serbian ACS cohort, clinical factors—particularly advanced age and impaired renal function—dominated the prediction of bleeding risk. The CYP3A5 signal was largely explained by baseline imbalances in age and renal function. CYP 3 A 4* 22 and CYP 4 F 2 polymorphisms did not contribute additional predictive information. Preemptive genotyping for these variants is unlikely to materially improve bleeding-risk assessment beyond standard clinical evaluation in patients of this type.